Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cosmos Health Inc. (COSM) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, giving investors structured access to its official record as a Nasdaq Capital Market issuer. Cosmos Health describes itself as a diversified, vertically integrated global healthcare group, and its filings reflect activity in pharmaceuticals, nutraceuticals, manufacturing, distribution, telehealth and digital assets.
Key documents include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited and interim financial statements, segment information tied to wholesale distribution, pharma manufacturing and branded products, as well as discussions of risk factors, liquidity and capital resources. Notifications such as the NT 10-Q filing explain delays in periodic reports and provide context on reporting timelines.
Cosmos Health also files numerous Current Reports on Form 8-K detailing material events. Recent 8-Ks cover topics such as record quarterly results, Nasdaq minimum bid price compliance notices, entry into a Securities Purchase Agreement for up to $300 million of senior secured convertible notes, the issuance of an initial $8 million note, governance and board changes, and shareholder approvals to increase authorized share capital and authorize a potential reverse stock split. These filings help investors track financing structures, capital allocation and corporate governance decisions.
Proxy materials like the DEF 14A definitive proxy statement provide information on director elections, executive compensation, equity incentive plans and shareholder proposals, including approvals related to the note financing and changes in authorized shares. Together with Form 4 insider transaction reports referenced in company news, these documents allow users to monitor ownership changes and board-level decisions.
On Stock Titan, COSM filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the main points of lengthy 10-K and 10-Q reports, explain complex financing terms in 8-Ks, and surface items such as bid price compliance, convertible note terms and voting outcomes. Users can quickly locate Forms 10-K, 10-Q, 8-K, DEF 14A and Form 4 filings, then rely on AI insights to understand how each filing may relate to Cosmos Health’s operations, balance sheet, governance and listing status.
Cosmos Health Inc. filed a current report to inform investors that its Chief Executive Officer has released an annual letter to shareholders for the year ended December 31, 2024. The letter, dated September 29, 2025, has been made available and is attached as Exhibit 99.1, providing additional context on the company’s strategy and outlook.
The company emphasizes that the CEO letter includes forward-looking statements about anticipated strategic plans and related outcomes, which are subject to risks and uncertainties. These statements are described as reflecting current intentions and expectations and may differ from actual future results. The information in the CEO letter and this report is being furnished under Regulation FD and is not deemed filed for liability purposes under the Securities Exchange Act.
Cosmos Health Inc. filed Amendment No. 1 to its shelf registration statement No. 333-290420 as an exhibits-only update. The company is adding as exhibits a Secured Convertible Promissory Note issued to M2B Funding Corp. dated June 9, 2025 and an August 6, 2025 amendment to that note, while leaving the prospectus unchanged and omitted from this filing.
The amendment also restates standard sections on offering expenses, indemnification of directors and officers under Nevada law and the company’s governing documents, and customary Securities Act undertakings for shelf offerings. The document is signed on behalf of Cosmos Health by Chief Executive Officer Grigorios Siokas and other senior officers and directors on September 22, 2025.
Cosmos Health Inc. is registering 78,637,352 shares of common stock for resale by investors that may receive these shares upon converting the company’s secured convertible notes. The shares include 72,159,091 shares tied to an August 2025 senior secured convertible note and 6,478,261 shares tied to a June 2025 secured convertible note. Based on a last sale price of $0.9319 on September 18, 2025, the registered shares have an indicated value of about $73.3 million. All sale proceeds will go to the selling stockholders, not the company. As of September 18, 2025, Cosmos had 31,013,876 common shares outstanding and is asking stockholders to approve an increase in authorized common shares to 1.5 billion. Conversion of the notes is subject to 4.99% or 9.99% beneficial ownership limits and could significantly increase the tradable float, with the company warning of high risk, potential dilution and stock price volatility.
Cosmos Holdings Inc. (COSM) discusses a proposed Reverse Stock Split and related considerations. The filing notes factors that could affect the historical and future trading price and volume of the Common Stock, including the anticipated market impact of the Reverse Stock Split and the company's ability to remain listed on Nasdaq. The company lists intended uses of any equity restructuring or capital-raising, including raising capital to fund operations and continue as a going concern, establishing strategic relationships, providing equity incentives to employees, officers or directors, and expanding via acquisitions or new product lines. The filing also explains that holders of registered book-entry shares need take no action to receive post-split shares; a transaction statement will be sent by the transfer agent after the Effective Date.
Andreas Bovopoulos reported beneficial ownership of 1,453,044 shares of Cosmos Health Inc. common stock, representing 4.823% of the class. The filing is a Schedule 13G/A dated for the event on 08/13/2025 and signed 08/19/2025. Bovopoulos reports sole voting and dispositive power over all shares and certifies the shares were not acquired to influence control of the issuer. The issuer's principal executive office is listed in Thessaloniki, Greece. The disclosure classifies this holding as ownership of 5 percent or less of the class and indicates no group affiliation, no subsidiary acquisition, and no holdings on behalf of another person.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,582,313 shares of Cosmos Health Inc. common stock, representing 4.99% of the class. Armistice Capital states it is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and by contract exercises voting and investment power over those shares; Mr. Boyd, as managing member, is likewise attributed shared voting and dispositive power. The filing indicates the holdings are reported as being held in the ordinary course of business and not for the purpose of changing control.
Cosmos Health Inc. entered into a Securities Purchase Agreement and, at the initial closing, issued a 9% original-issue-discount senior secured convertible promissory note with an aggregate original principal amount of $8,000,000. The Initial Note matures on August 7, 2027 and bears interest at 9% per annum, computed on a 360-day year and payable in arrears monthly on the first calendar day of each month beginning September 1, 2025. Interest may be paid in shares of common stock, in cash, or a combination, subject to the Note's Equity Conditions.
The Initial Note is convertible into shares of common stock; the Conversion Shares are determined by dividing the Conversion Amount by the lower of the Conversion Price of $1.05 and the Market Price. The holder faces a Beneficial Ownership Limitation of 4.99% of outstanding common stock immediately after conversion (adjustable up to 9.99% after notice, effective 61 days after notice). The Note ranks senior to other indebtedness except permitted indebtedness, contains customary events of default that raise the interest rate to 16% upon default, and was sold in a private offering under Section 4(a)(2) of the Securities Act. The form of the Note is filed as Exhibit 4.1.